Welcome to Markets Desk, let's get you caught up on what's moving.
Strategy shares dropped as much as six percent Monday morning despite the firm disclosing yet another bitcoin purchase, this time four hundred eighty five coins at an average of sixty eight thousand eight hundred eighty seven dollars each, totaling thirty three point four million dollars. The market's reaction likely reflects the notably smaller scale of the buy compared to the prior week's purchase of over a thousand coins, raising questions about whether the pace of accumulation is slowing.
On the broader crypto picture, Bitwise CIO Matt Hougan is warning that bitcoin could see further near-term weakness, even as he maintains it remains the best risk-adjusted trade of the coming decade. That cautious short-term tone aligns with a separate note flagging record hedge fund leverage as a potential cross-market spillover risk for bitcoin heading into the first quarter of two thousand twenty six.
Meanwhile, in a story with genuine clinical weight, Alpha Tau Medical reported interim results from its U S brain cancer trial showing complete tumor clearance in five of eight recurrent glioblastoma patients assessed under standard imaging criteria. That is a rare and striking signal in one of oncology's hardest-to-treat indications, and shares of the company will be worth watching closely.
That's the tape. Markets Desk, signing off the floor.
